Oct 12, 2026 · 49 min
Biotech investors weigh AI, China, and clinical execution
AI, China, And Biotech Investing With SR One's Simeon George, M.D.
The episode shows how biotech capital allocation is changing as AI, China’s development capabilities, and geopolitical uncertainty reshape drug creation.
- 1SR1 prioritizes exceptional founders, transparent leadership, and platforms that translate into focused clinical products.
- 2AI’s near-term value may lie in improving development decisions and forecasting late-stage outcomes, not merely generating impressive tools.
- 3China’s growing infrastructure is pushing biotech toward globally distributed development strategies that balance science, capital efficiency, and geopolitical risk.
Don't miss
George explains why China’s development advantage requires biotech companies to choose partners and locations situationally rather than follow a fixed geographic playbook.
The brief
Simeon George, cofounder and CEO of SR1 Capital Management, traces his path from medicine, banking, and consulting to biotech investing and company building.
SR1’s investment framework combines founder quality, transparency, platform-to-product translation, clinical strategy, and pharmaceutical connectivity across therapeutic areas and development stages.
George argues that AI should improve repeated development decisions and late-stage prediction, with R&D leaders defining problems alongside AI-native technical experts.
China’s improving drug-development infrastructure is forcing Western companies to consider transnational strategies that use the most efficient locations and partners.
The standout tension is strategic rather than technological: biotech leaders must integrate AI and China while preserving scientific judgment, trial integrity, and first-principles reasoning.
What was said on this episode
26 statements · 19 positive · 4 negative · 1 mixed · 2 neutral
SR1 generated strong financial returns during its GSK corporate-venture period.
“The fund did incredibly well from a financial return standpoint.”
Listen at 6:18
SR1 manages more than $2 billion across multiple funds.
“we now manage over 2 billion across multiple funds”
Listen at 9:03
SR1 invests across company creation through late-stage private or public opportunities.
“we think of ourselves as end-to-end investors”
Listen at 11:30
Viridermics’ phase-three trials succeeded and its female phase-two study showed hair regrowth.
“the company has had an incredible year this year. Phase threes have hit. The phase two in women has also shown ability to regrow hair.”
Listen at 12:28
Viridermics was the year’s best-performing IPO at that point.
“I think it's been the best performing IPO of any IPO that's happened this year.”
Listen at 12:40
Viridermics was the year’s best-performing IPO at that point.
“the best performing IPO of any IPO that's happened this year”
Listen at 12:40
SR1 invests in platforms only when focused on medicines addressing specific unmet needs.
“the platform has to be focused around a medicine in a particular unmet need that we believe is going to create significant value if we can hit that target product profile”
Listen at 14:16
Arcellx’s treatment potentially offers a cure for multiple myeloma.
“you've got potentially a curative treatment for multiple myeloma right now”
Listen at 14:58
Gilead paid for half of Arcellx’s product rights.
“Gilead has paid. For half of the product rights this year”
Listen at 15:11
Zhen Li is an exceptional leader for translating RNA technology into products.
“there is no one you'd rather bet on to develop a technology and turn it into a product than someone like that”
Listen at 21:05
Insufficient founder transparency or trust is a major investment red flag for SR1.
“there isn't the level of transparency or trust that you're building with the founder or entrepreneur”
Listen at 23:04
AI’s greatest near-term drug-development impact is improving early decisions and late-stage predictions.
“we believe that is where there's the most dynamic ability to impact which patients, how to enrich, which markers”
Listen at 25:04
AI-enabled biotech companies should begin with a defined patient or product problem.
“you have to start with what is the problem you're solving?”
Listen at 26:19
Biotech companies should begin with patient problems and use AI as a supporting tool.
“you have to start with what is the problem you're solving? And then what are all the ways you're going to leverage China, AI, whatever it is, these are tools to ultimately get to what matters”
Listen at 26:19
AI adoption in biotech should be led by development experts supported by AI-native technical staff.
“our belief is you need to start with someone that really understands development”
Listen at 28:15
Biotech organizations should build AI around core drug-development expertise.
“You start with the core development capability and then you add technology around it.”
Listen at 28:51
Dynamic AI-driven product-profile management will be easier in startups than large pharma.
“it's absolutely going to be easier to do this in a startup, smaller company setting than it is in an organization of 10,000 or 15,000 R&D employees in large pharma”
Listen at 31:21
China’s drug-development capabilities could deliver medicines faster and at lower cost.
“medicines that are going to get to them hopefully faster, sooner, and ideally costing less”
Listen at 33:33
China’s drug-development cost and speed advantage over Western development is narrowing.
“that spread is getting thinner by the day”
Listen at 34:14
Drug development is likely to shift toward transnational frameworks using multiple countries.
“it's probably a transnational development framework that we are likely moving towards”
Listen at 36:15
China must be included in global drug-development strategies.
“China is for sure a global player now. We have to have it as part of our ultimately developing strategy in some way, shape or form.”
Listen at 38:57
China is now an established global player in drug development.
“China is for sure a global player now”
Listen at 38:57
Transnational development including China should be encouraged with safeguards.
“we should be encouraging it as long as there are the appropriate checks and balances along the way”
Listen at 39:49
SR1 has invested in eight companies with China-sourced assets.
“we've now invested in, I think, eight companies where assets have been sourced from China”
Listen at 40:14
Cuts to NIH funding could harm U.S. long-term scientific and industry innovation.
“what I worry about in the U.S. is basic research, for example, the NIH, like having cuts there that ultimately will have a union to long-term effect”
Listen at 43:35
Clinical-trial betting markets should not affect patient enrollment or retention.
“you want to make sure that this does not have an impact in any way, shape or form on how patients are continuing to enroll and stay in these trials”
Listen at 46:01
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.